Navigation Links
Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
Date:8/18/2009

WELLESLEY HILLS, Mass., Aug. 18 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the PRX-08066 Therapeutics Program in Phase 2 for respiratory indication will be part of the intellectual property offered for sale at the September 30, 2009 auction.

The PRX-08066 is a Therapeutics Program in Phase 2 for respiratory indication. It is a small molecule, oral 5HT2b antagonist for potential treatment of pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD). There is significant reduction in SPAP in conditioned athletes (hypoxia challenge) and in subjects with PH/COPD. There is potential indication for pulmonary arterial hypertension (PAH) including in diastolic dysfunction.

The intellectual property, regulatory dossier and clinical inventory will be sold at auction on September 30, 2009.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc. and Prospect Therapeutics, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@earthlink.net


'/>"/>
SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
2. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
3. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
6. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
7. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
8. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
9. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
11. Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 Sinovac Biotech Ltd. ("Sinovac" or the "Company") ... China , today announced that its board of directors has ... the plan from March 27, 2017 to March 27, 2018. The amendment ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a China ...
(Date:3/23/2017)... ... 23, 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building cooking ... for companies around the world, such as Illumina, HP and Qualcomm, and is ranked #1 ... increasing popularity is due to its new team building format, a way for teams to ...
(Date:3/23/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... reported financial results for the quarter and year ... update on the company,s clinical development efforts and ... pleased to report that last year was a ... Krammer. "We achieved key clinical milestones and attracted ...
(Date:3/23/2017)...  Agriculture technology company Cool Planet has closed on ... to commercialize its Cool Terra and Cool Fauna Engineered ... that are simultaneously profitable as well as sustainable and ... months. This latest round of funding was led by ... The company,s primary product, Cool Terra, can improve ...
Breaking Biology Technology:
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
(Date:3/6/2017)... SAN MATEO, Calif. , March 6, 2017 ... predictive marketing and sales technology, today announced Predictive ... (AI) solution for infusing actionable sales intelligence into ... customers to automatically enable their sales organizations with ... contextual messages that allow for intelligent engagement. Predictive ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
Breaking Biology News(10 mins):